Valerio Therapeutics
C4X
Company Profile
Business description
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using two proprietary platforms: the PlatON platform and its DNA decoy mechanism of action, and the V-Body platform generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-ofconcept, a value-creating inflection point appealing to potential partners. Its pipline includes Metabolic Diseases, Immunology & Inflammatory, and Oncology.
Contact
49, Boulevard du General
Martial Valin
Paris75015
FRAT: +33 145587600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
25
Stocks News & Analysis
stocks
Market pricing in further upside in overvalued ASX bank
We view the shares are materially overvalued.
stocks
Chart of the Week: Lithium is rebounding on rising demand
The mining sector is significantly overvalued on average but select value to be found.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,316.60 | 23.80 | -0.25% |
| CAC 40 | 8,361.56 | 67.47 | -0.80% |
| DAX 40 | 25,060.11 | 218.10 | -0.86% |
| Dow JONES (US) | 49,662.66 | 129.47 | 0.26% |
| FTSE 100 | 10,617.86 | 68.32 | -0.64% |
| HKSE | 26,705.94 | 138.82 | 0.52% |
| NASDAQ | 22,753.63 | 175.25 | 0.78% |
| Nikkei 225 | 57,467.83 | 323.99 | 0.57% |
| NZX 50 Index | 13,444.20 | 197.18 | 1.49% |
| S&P 500 | 6,881.31 | 38.09 | 0.56% |
| S&P/ASX 200 | 9,086.20 | 24.30 | -0.27% |
| SSE Composite Index | 4,082.07 | 51.95 | -1.26% |